International congresses

Oral & Poster Abstracts :

Launay O, Boucherie C, Duvivier C, Leautez-Nainville, Verdon R, Chene G, Fagard C for the ANRS 2h Study group.
Pandemic H1N1v and Seasonal Influenza and Pneumococcal Vaccination Coverage in French HIV-Infected Adults during 2009 Pandemic: ANRS 2H Study.
51th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago USA

Loulergue P, Roussseau B, Mir O, Viel E, Krivine A, Goldwasser F, de Gramont A, Launay O, Tournigand C.
Immunogenicity and safety of two doses of AS03A-adjuvanted influenza A H1N1v 2009 vaccine in cancer patients on chemotherapy - VACANCE study.
21th ECCMID, Milan, May 7-10, 2011.

Durier C, Desaint C, Colin de Verdière, Girard PM, Lévy Y, Rey D, Jacomet C, Lucht F, Aboulker JP, Launay O,
for the ANRS 151 study group and the REIVAC network.
Durier C, Desaint C, Silbermann B, Lelièvre JD, Slama L, Morineau-Le Houssine P, Cuzin Lise, Poizot-Martin, Aboulker J P, Launay O
for the ANRS COV1-COHVAC Study Group.
Durability of the Immune Response after Vaccination with Two Doses of Influenza A H1N1v 2009 Vaccine Formulated with and without AS03A-Adjuvant in HIV-infected Adults: the ANRS 151 Randomized HIFLUVAC Trial. Long term vaccine-induced HIV seropositivity amoung HIV uninfected healthy volunteers in ANRS COV1-COHVAC cohort.
18th Conference on Retroviruses and Opportunistic Infections; Boston; February 27-March 2, 2011

Launay O, Capitant C, Schmitz T, Chazallon C, Riethmuller D, Picone O, Poulain P, Lewin F, Jacqz-Aigrain E, Aboulker JP, Tsatsaris V, for the Inserm C09-33 PREFLUVAC study group for the Inserm PREFLUVAC Trial Group.
Strong Immune Response to a Monovalent non-Adjuvanted 2009 Influenza A/H1N1v Vaccine in Pregnant Women.
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, USA, September 12-15, 2010

Launay O, Desaint C, Durier C, Loulergue P, Duval X, Pialoux G, Ghosn J, Raffi F, Reynes J, Aboulker JP. Launay O, van der Vliet D, Rosenberg A, Michel ML, Lortholary O, Colin de Verdière N, Slama L, Piroth L, Rey D, Carrat F. Levy Y, Ellefsen K, St?ehr W, Bart PA, Lelièvre JD, Launay O, Wolf H, Weber J, ChÍne G, Pantaleo G.
Immunogenicity of One Dose of Influenza A H1N1v 2009 Vaccine Formulated with and without AS03A-Adjuvant in HIV Adults: Preliminary Report of the ANRS 151 Randomized HIFLUVAC Trial.
A Randomized Controlled Trial Comparing the Efficacy and Safety of 4 Intramuscular Double Doses or 4 Intradermal Low Doses with 3 Intramuscular Standard Doses of Hepatitis B vaccine in HIV-infected adults: Results of the ANRS HB03 VIHVAC-B Trial.
Optimal Priming of Poxvirus Vector (NYVAC)-based HIV Vaccine Regimens Requires 3 DNA Injections. Results of the Randomized Multicentre EV03/ANRS Vac20 Phase I/II Trial.
17th Conference on Retroviruses and Opportunistic Infections; San Francisco, California; February 16-19, 2010

Salmon-Ceron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hénin Y, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Ben Hamouda N, Jackson A, Flys C, Guérin C, Aboulker JP, Choppin J, Launay O.
Safety and Immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: Results of ANRS VAC18, a Phase 2, Randomized, Double-Blind, Placebo-Controled Trial.
AIDS Vaccine 2009; Paris, France, October 19-22nd 2009.

Loulergue P, Kernéis S, Tsatsaris V, Jarreau PH, Cabrol D, Launay O.
Perinatal Vaccine-preventable Diseases: Insufficient Knowledge Among Healthcare Workers.
49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA, September 12-15-2009.

Belarbi L, Loulergue P, Calmus Y, Conti F, Grabar S, Meritet JF, Rosenberg A, Launay O.
Immunogenicity of hepatitis A and B vaccines among liver transplant candidates.
19th ECCMID, Helsinski, Finland, May 16-19, 2009.


 

Page lue en 0,0453 seconde (5/0)